The Cyber Due Diligence Question That Can Damage a Biotech Valuation
Biotech leaders often assume cyber due diligence is a documentation exercise: provide the policies, list the tools, confirm backups exist, and move forward.
That belief is dangerously incomplete.
Serious investors, strategic partners, insurers, and acquiring companies are not only asking what controls exist. They are trying to determine whether the company can detect, investigate, contain, and explain an incident before it damages the asset they are evaluating.
For a biotech company under $100 million in revenue, the answer may expose a serious weakness. The organization can hold valuable intellectual property, sensitive research data, external laboratory connections, cloud platforms, and contract research organization relationships while relying on a small IT team carrying several jobs.
The diligence question that exposes the gap is simple:
Who is qualified to investigate a credible security alert after hours?
When the answer is unclear, the problem is no longer technical. It raises questions about operational maturity, research continuity, management oversight, and whether leadership has understated the company’s exposure.
Investors Are Not Buying Your Security Tools
A biotech company can have endpoint protection, firewalls, multifactor authentication, cyber insurance, written policies, and an incident response plan and still be unable to respond effectively at 2:00 a.m.
Tools generate evidence. They do not interpret it, determine business impact, coordinate containment, or brief executives.
The SEC requires public companies to disclose material cybersecurity incidents and describe their processes for managing material cyber risk, management’s role, and board oversight. Public companies generally must file an incident disclosure within four business days after determining materiality. These rules apply directly to public registrants, but they also illustrate the governance discipline investors now expect.
The issue is not whether every early-stage biotech must operate like a public company. It is whether leadership can explain its risk without exposing an operating model built on assumptions.
The Weak Answer Sounds Responsible
Many biotech companies answer after-hours questions this way:
“Our tools operate continuously.”
“Our IT director receives alerts.”
“We have an incident response plan.”
Each statement may be true. None proves that a qualified analyst is continuously available to investigate an alert.
A diligence reviewer should push further:
Who receives the alert? How quickly must a human review it? Can that person distinguish a false positive from account compromise or data exfiltration? Who can disable an account or isolate a device? What happens when the designated employee is asleep, traveling, sick, or already handling another emergency?
Vague answers reveal that the company owns security technology but may not have a complete security operation.
The Valuation Risk Begins With Uncertainty
Cybersecurity does not have to become a catastrophic breach to affect an investment or partnership conversation. Uncertainty creates friction.
An investor wants confidence that the company can protect the research, systems, and relationships supporting future value. A strategic partner wants assurance that shared information or connected systems will not introduce unmanaged exposure. An insurer wants evidence that controls function, not merely that they were purchased.
Weak answers can lead to additional reviews, remediation requirements, tighter contractual terms, increased insurance scrutiny, delayed decisions, or concern about management maturity.
The security gap becomes a valuation issue because leadership cannot quantify how long a threat could remain uninvestigated.
NIST’s Cybersecurity Framework 2.0 organizes cybersecurity around Govern, Identify, Protect, Detect, Respond, and Recover. A company that invests in protection but cannot reliably detect and respond after hours has not completed the operating cycle.
A Public Incident Shows Why Evidence Matters
In April 2023, Enzo Biochem disclosed that ransomware affected certain information technology systems. The company disconnected systems from the internet, engaged third-party cybersecurity experts, and later reported that data had been accessed and, in some cases, exfiltrated.
Later filings described regulatory inquiries and class-action litigation connected to the incident.
The point is not that every biotech company will experience the same event.
The point is that once an incident moves beyond a contained technical alert, the consequences can expand into legal, regulatory, operational, reputational, and executive-level workstreams.
During due diligence, leaders should be able to demonstrate what would prevent an alert from becoming a multi-front business problem.
The Evidence Leadership Should Produce
Strong answers are supported by evidence, not confidence.
Biotech security leaders should be prepared to produce:
- Actual staffed coverage hours, not software uptime.
- Defined alert-severity and escalation thresholds.
- Human acknowledgement and investigation targets.
- Night, weekend, and holiday procedures.
- Named authority for account suspension and endpoint isolation.
- Recent examples of investigated alerts.
- Incident-response exercise results.
- Backup-restoration test results.
- Third-party and privileged-access reviews.
- Metrics showing how quickly high-risk activity is investigated.
CISA describes an incident response plan as a document that helps an organization before, during, and after a suspected or confirmed incident. But the document still requires people who are available, qualified, and authorized to execute it.
A plan that cannot be activated at 2:00 a.m. is not a response capability. It is paperwork.
Managed Security Is an Operating Decision
A biotech company under $100 million may not have the budget or hiring depth to build a fully staffed internal security operations center.
Pretending otherwise does not remove the exposure.
A managed or co-managed security model can provide continuous monitoring, experienced investigation, defined escalation paths, response commitments, and defensible reporting.
The internal team retains business knowledge, strategic control, and decision authority. The managed security team provides the coverage and specialized capacity that should not be placed on one overloaded IT leader.
That is not outsourcing responsibility.
It is defining responsibility.
Before selecting a provider, leaders should examine whether “response” means an automated ticket, a human acknowledgement, an active investigation, or containment.
They should also evaluate:
- Coverage exclusions.
- Analyst experience.
- Technology integrations.
- Escalation procedures.
- Containment authority.
- Reporting quality.
- Contractual response commitments.
- Procedures for reaching internal leaders after hours.
A dashboard is not evidence of a mature operating model. Measurable human action is.
The Question Leadership Cannot Avoid
Cyber due diligence does not punish a biotech company for being small.
It exposes whether the company has built a security model appropriate for the value, intellectual property, research activity, and operational dependency it has already created.
The question is not whether your team can complete another questionnaire.
It is whether your answers remain credible when an investor asks for proof and whether someone qualified is watching when the most important alert arrives after hours.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
